The three bands of LATAM regulatory translation: where Amavita Sciences fits between the freelancers and the Big Four

Why this post exists

In June 2026, bioaccess® ran a formal RFP for English-to-Spanish medical device translation across Latin America. We invited a wide cross-section of the market: US-based LSPs with LATAM operations, in-country language service providers in Panama, Ecuador, Argentina, and Costa Rica, sworn peritos, and a long tail of individual translators. We shared a real MedTech sample package, real page volumes, and a real steady-state pipeline of three to six thousand pages per month.

That RFP taught us something the marketing pages of the industry will not: the LATAM regulatory translation market is not one market. It is three.

At the bottom band, priced between five and fourteen cents per source word, sits a large and fragmented population of individual translators and small regional agencies. They compete on price and personal relationships. They are almost never fit for sophisticated regulatory work.

At the top band, priced between twenty-eight and forty-five cents per source word for enterprise engagements, sit the Big Four global life sciences LSPs: TransPerfect, RWS, Lionbridge, and Welocalize / Welo Life Sciences. They have brand, global footprint, and process. They also have public LATAM coverage that ranges from thin to nonexistent — a fact we can now demonstrate page by page.

This post explains the three bands. It names names. It cites everything. And it explains why the middle band is where the work belongs.

Band 1: the LATAM freelancer and boutique floor ($0.05 – $0.14 / word)

Our June 2026 RFP surfaced live pricing across this band. These are quotes we actually received against a real sample package, not marketing collateral. What the responses share is a floor between five and fourteen cents per source word, with tight geographic and human-capital footprints.

These are competent linguists. Several are certified peritos or sworn public translators recognized by their national judiciaries. That is not the problem. The problem is what the price point structurally cannot buy.

At $0.05 to $0.14 per source word, a vendor cannot fund:

• A deterministic QC layer that runs on every deliverable regardless of translator.
• A cryptographic audit ledger that produces tamper-evident hashes for every batch.
• A guarantee mechanism that pays the client cash when the vendor is late.
• Parallel fan-out across twelve LATAM regulators from a single origin dossier.
• Dedicated regulatory affairs review of translated content prior to release.
• HIPAA-eligible zero-data-retention infrastructure on a hyperscaler.
• Per-client translation memory and glossary retention with versioned drift monitoring.

What that price does buy is a translator. Sometimes an excellent one. Working at their own capacity, on their own schedule, with their own local review practices — most of which reduce to the translator reading it twice.

For a birth certificate, that is enough. For Instructions for Use governing a Class III implantable device across nine LATAM regulators, it is not. We say this without contempt for individual translators. We work with them; several are on our vendor roster today. What we do not do is confuse a translator with a regulatory translation platform. They are one person. The work requires an infrastructure.

Band 2: the Big Four global LSPs ($0.28 – $0.45 / word)

At the top of the market sit the four global life sciences LSPs a submissions manager in Basel, Cambridge, or Bridgewater has heard of. All four are real, credentialed, and larger than Amavita Sciences will be for a long time. Enterprise buyers pay them enterprise rates. Here is what we actually found, page by page, when we read their public positioning against LATAM regulatory work.

TransPerfect

The largest player in the industry, with $1.32 billion in 2025 billed revenue, up 7% year over year. Life Sciences positions itself as “Global Content Solutions for Life Sciences”, and the dedicated Life Sciences microsite markets GlobalLink TMS as the enabling platform. LATAM appears once — as a phrase in a bullet about labeling savings referencing “dossiers in Latin America or Asia”. No LATAM regulator is named. Not COFEPRIS, INVIMA, ANMAT, ANVISA, DIGEMID, ISP, ARCSA, AMS, MINSA, MoH-DR, MoH-Uruguay, or MoH-Paraguay.

Quality assurance is described in a blog as three methodologies — translator, editor, proofreader — plus back translation and linguistic validation. There is no numbered gate architecture, no cryptographic ledger, no first-pass acceptance guarantee, and no published turnaround SLA for regulatory content. HIPAA is claimed only for the AI data collection and annotation line. Structurally, in 2025 traditional language services fell below 50% of total revenue for the first time. That does not make TransPerfect a worse translator. It does make LATAM regulatory a smaller share of the attention budget.

RWS

The former SDL Life Sciences business generated £690.1m in FY25 revenue, down 4% reported, and now describes itself as a global AI solutions company. RWS is the only one of the four that publishes a checkpoint count: six Quality Assurance checkpoints across a four-phase process, plus an eleven-step linguistic validation process.

That is real methodology. It is also role-based, not failure-class-based: the six checkpoints are described by phase, not by the error taxonomy each gate blocks. No numeric-integrity gate. No unit-consistency gate. No negation-preservation gate. No entity-mapping gate. No adversarial back-translation running as an automated production gate. No LATAM regulator is named on any RWS page we could retrieve. Security posture is ISO 27001:2022 certified; HIPAA-eligible workflows, zero-data-retention commitments, and BAA availability are not claimed. RWS shed 410 FTE in FY25 while Regulated Industries revenue fell 12% reported.

Lionbridge

Now under KKR ownership as of February 2026, with a new CEO effective May 2026 and over 6,000 employees in 25 countries. Lionbridge is the strongest of the four on published HIPAA posture — HIPAA-compliant workflows safeguarding PHI — but note the scope: that claim sits on the Healthcare page, oriented toward interpreting and healthcare access, not regulatory submission translation.

On LATAM, regulatory expertise is explicitly weighted toward US and EU: “expertise with all US and EU Regulations… centralized and decentralized procedures”. No LATAM regulator is named. Lionbridge is the only Big Four vendor with published per-word pricing, but only on non-life-sciences products — $0.06 standard and $0.12 advanced on Gengo. That transparency does not extend to regulated work.

Welocalize (Welo Life Sciences)

Rebranded in April 2026 as Welo Global, publishing 99.2% on-time delivery, 99.8% compliance, 500M words translated. Welocalize is the only one of the four with a real LATAM regulator case study — batch records submitted to ANVISA under compressed timelines. That is a genuine LATAM regulatory win. It is also ANVISA only: their regulatory submission page lists EMA, Health Canada, Swissmedic, Taiwan FDA, South Korea MFDS, Russia’s register, and FDA SPL — and no other LATAM authority.

On turnaround, Welocalize publishes more than any other Big Four vendor, but for adjacent products: 24-hour delivery for pharmacovigilance and expedited safety translations. Regulatory submission turnaround is procedural, not numeric. HIPAA is not on their published compliance list.

What the Big Four collectively claim — and don’t

Sources for every row are inline in the vendor sections above. If you want to check us, click the links; we will not persuade you by paraphrase.

Band 3: Regulatory Language Infrastructure ($0.19 – $0.38 / word)

Between the freelance floor and the enterprise LSP ceiling sits a category that did not exist before we built it. Not a bigger boutique. Not a cheaper Big Four. Regulatory Language Infrastructure™ — a translation platform in which the platform itself is the deliverable, and the human translator certifies the outcome rather than producing the first draft.

Seven deterministic QC gates, named by failure class

1. Structural inventory — every heading, section, table, cross-reference, and embedded artifact accounted for.
2. Numeric integrity — every value, unit, decimal, and range compared byte-for-byte across source and target.
3. Unit consistency — SI conversions, unit strings, and locale-specific decimal separators normalized and verified.
4. Negation preservation — every negation, contraindication, and prohibition compared for polarity inversion.
5. Entity mapping — every proper noun, drug name, device name, and regulatory entity resolved against a maintained glossary.
6. Adversarial back-translation — a separate model translates the target back to source, and reconciliation flags anywhere the round trip drifts.
7. Document Currency — every foreign-issued document (CPP, CLC, GMP certificate, apostille) verified within its jurisdictional validity window at the moment of filing.

None of the Big Four publishes a QC architecture organized this way. RWS publishes six checkpoints organized by phase; we publish seven gates organized by the error each one blocks. A phase-organized process tells you when review happens. A failure-class-organized process tells you what a document has to survive before it leaves the platform.

Cryptographic audit ledger

Every batch we release carries a SHA-256 fingerprint. Every version we produce is signed. Every audit is prepackaged. None of the Big Four publishes a cryptographic delivery artifact. Their audit story is ISO certification plus signed certificates of translation. Both matter. Neither is a hash.

All-or-nothing batch release

We do not deliver a partially-QC’d batch. If any gate fails on any document in a batch, the batch does not release. The Big Four pattern is rolling delivery with parallel QC — faster on average, worse under adversarial submission conditions. When a regulator returns a Request for Information because a numeric mismatch survived to the dossier, “faster on average” is not the metric that matters.

First-Pass Acceptance Program (Tier 1-A)

$2,500 per business-day credit if a Tier 1-A batch is rejected by the target regulator on translation grounds, with a 48-hour re-issue SLA. This is not marketing: it is a contractual risk-transfer instrument written into the Tier 1-A agreement. Not a single Big Four vendor publishes a comparable financial guarantee. Their commitments are process-based. Ours is cash-denominated.

Twelve LATAM regulators, parallel fan-out from one origin

One origin-language dossier fans out to COFEPRIS, INVIMA, DIGEMID, ANMAT, ISP, ARCSA, AMS, MINSA, MoH-DR, MoH-Uruguay, MoH-Paraguay, and ANVISA — in parallel, from one translation memory, with one terminology decision resolved once and reused everywhere. Not one of the Big Four names more than one LATAM regulator on its public pages.

HIPAA-eligible zero-data-retention infrastructure

BAA available. No third-party training on client content. Direct source-to-target from eight source languages — no English pivot, ever. Model routing on hyperscaler infrastructure with zero-data-retention configuration guaranteed by vendor contract, not by promise. Lionbridge publishes HIPAA workflows scoped to healthcare interpreting; TransPerfect claims HIPAA for its AI data annotation line. Neither is HIPAA-eligible regulatory translation with ZDR.

The economic frame

Consider the same 500-page pilot batch (≈125,000 words) under each band:

At Tier 1-A we are inside the Big Four price envelope while delivering LATAM regulator depth none of them publishes and audit artifacts none of them produces. At Tier 1-B we sit above the LATAM floor at roughly triple the individual translator rate — and that premium buys everything the individual translator cannot fund at $0.05: the QC gates, the ledger, the fan-out, the guarantee. That is the specialist-middle argument. Not a compromise. A category.

When each band is the right answer

We are not going to tell a buyer that Amavita is always the answer. We built the platform. We know the answer.

• Choose Band 1 when the document is procedurally simple, the regulator does not audit translation-grounds rejections, the risk of a Request for Information is low, and per-word cost dominates every other consideration. Birth certificates. Non-technical marketing. Internal notes. One-off letters.
• Choose Band 2 when you are a top-twenty pharma running global submissions through a preferred vendor list, your regulatory function requires a single supplier of record with global footprint and enterprise procurement scaffolding, and LATAM is one submission among dozens in an EMA-centered portfolio.
• Choose Band 3 when LATAM is not an afterthought: three or more LATAM jurisdictions, multi-country parallel filings from a single origin dossier, a translation-grounds rejection that would delay first-patient-in by weeks, an auditor who needs cryptographic proof rather than a certification badge, and a written cash credit if the platform misses.

That third case is the one no Band 1 vendor can serve, and the one no Band 2 vendor has publicly built for.

The honest positioning statement

Amavita Sciences™ is not the cheapest LATAM translation option. Ocean Translations is cheaper. Translators Ecuador is cheaper. If per-word cost is the whole objective function, we are not your answer.

Amavita Sciences™ is not the biggest global LSP. TransPerfect is $1.32 billion. RWS is £690 million. We are not going to out-headcount them. If procurement is running a vendor-consolidation exercise across a hundred languages and thirty industries, we are not your answer either.

The freelance floor cannot afford to build this. The Big Four have not chosen to. We did.

Notes on posture. Amavita Sciences™ operates under Part 11 readiness (not certified). Our translation infrastructure is HIPAA-eligible via BAA — not “HIPAA-compliant,” since no such certification exists for language service providers. We use zero-data-retention model configuration. We do not describe ourselves as an AI translation company. Public Big Four data is as of August 2026; LATAM pricing data comes from the bioaccess® EN→ES medical device RFP of June 2026.

Estimate your own submission

The same model that powers our full estimator, running inline. Adjust the inputs to see where your dossier lands against the bands above.

Frequently asked questions

What are the three bands of the LATAM regulatory translation market?

Band 1 is the freelance and boutique floor at roughly $0.05 to $0.14 per source word. Band 2 is the Big Four global life sciences LSPs — TransPerfect, RWS, Lionbridge, and Welo Life Sciences — at roughly $0.28 to $0.45 per source word for enterprise engagements. Band 3 is Regulatory Language Infrastructure, priced at $0.19 to $0.24 for Tier 1-B and $0.30 to $0.38 for Tier 1-A.

Where does the pricing data come from?

From a formal RFP bioaccess ran in June 2026 for English-to-Spanish medical device translation across Latin America, using a real MedTech sample package, real page volumes, and a steady-state pipeline of three to six thousand pages per month. Band 1 quotes are live quotes received against that package, not marketing collateral. Big Four figures come from public pages and filings as of August 2026.

What can a $0.05 to $0.14 per-word vendor not fund?

A deterministic QC layer applied to every deliverable regardless of translator, a cryptographic audit ledger, a cash-denominated delay guarantee, parallel fan-out across twelve LATAM regulators from one origin dossier, dedicated regulatory affairs review, HIPAA-eligible zero-data-retention infrastructure, and versioned per-client translation memory with drift monitoring. What the price buys is a translator — sometimes an excellent one.

Do the Big Four cover LATAM regulators?

Thinly, on their public pages. Welocalize is the only one with a real LATAM regulator case study, and it is ANVISA only. TransPerfect, RWS, and Lionbridge name no LATAM regulator on any page we could retrieve; Lionbridge's regulatory expertise is explicitly weighted toward US and EU procedures.

How are seven deterministic QC gates different from RWS's six checkpoints?

RWS publishes six checkpoints organized by phase — who reviews when. Amavita publishes seven gates organized by failure class: structural inventory, numeric integrity, unit consistency, negation preservation, entity mapping, adversarial back-translation, and Document Currency. A phase-organized process tells you when review happens; a failure-class-organized process tells you what a document has to survive before it leaves the platform.

What is the First-Pass Acceptance Program?

A contractual risk-transfer instrument in the Tier 1-A agreement: a $2,500 per business-day credit if a Tier 1-A batch is rejected by the target regulator on translation grounds, with a 48-hour re-issue SLA. No Big Four vendor publishes a comparable cash-denominated financial guarantee; their commitments are process-based.

When should a buyer not choose Amavita Sciences?

When the document is procedurally simple and per-word cost dominates every other consideration — a freelance translator is the right answer there. Or when procurement requires a single global supplier of record across a hundred languages and thirty industries, with LATAM as one submission among dozens in an EMA-centered portfolio — the Big Four earn that work.

Related reading

• Why regulatory translation is not a translation project — the infrastructure argument behind the Band 3 category.
• Translation QC for regulatory dossiers — what the seven gates are designed to catch, document by document.
• Preclinical translation requirements across 9 LATAM regulators — the regulator-level detail behind the fan-out claim.
• The LATAM regulatory translation matrix — tiering reference across the LATAM authorities.
• How the platform works — gates, ledger, and batch release semantics in practice.
• Sworn vs. certified translation for regulatory submissions — which certification each LATAM regulator actually accepts.
• The costliest translation mistakes in regulatory filings — the error classes that trigger RFIs and how to catch them.

Related articles

• LATAMPreclinical Translation Across 19 LATAM CountriesWhat LATAM regulators and ethics committees actually require translated for the preclinical annex of clinical trial filings — 19 countries, 5 exceptions named.August 25, 2026 · 10 min read
• LATAMINFLESZ Threshold: Why 98% of Spanish ICFs FailThe Spanish-specific readability index LATAM IRBs increasingly enforce — and why 98.3% of Spanish ICFs already fail it.August 21, 2026 · 13 min read
• LATAMThe RFI Anatomy: Six LATAM Rejections DeconstructedSix real translation-grounds RFIs from INVIMA, ANVISA, COFEPRIS, ANMAT, ISP and DIGEMID: the flagged clause, the error, and the delay each caused.August 21, 2026 · 16 min read